What 8 Analyst Ratings Have To Say About Globus Medical
Portfolio Pulse from Benzinga Insights
Analysts have provided various ratings for Globus Medical (NYSE:GMED) within the last quarter, with 2 bullish, 2 somewhat bullish, and 4 indifferent. The average 12-month price target for the company is $68.75, a decrease of 0.07% from the previous average price target of $68.80.

October 20, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mixed analyst ratings and a slight decrease in the average price target could lead to uncertainty among investors, potentially impacting Globus Medical's stock price.
The mixed analyst ratings indicate differing opinions about the company's performance, which could lead to uncertainty among investors. Additionally, the slight decrease in the average price target, although not significant, could be perceived negatively by some investors, potentially impacting the stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100